First-in-man Safety and Efficacy of the Adipose Graft Transposition Procedure (AGTP) in Patients With a Myocardial Scar

Antoni Bayes-Genis, Paloma Gastelurrutia, Maria-Luisa Cámara, Albert Teis, Josep Lupón, Cinta Llibre, Elisabet Zamora, Xavier Alomar, Xavier Ruyra, Santiago Roura, Ana Revilla, José Alberto San Román, Carolina Gálvez-Montón, Antoni Bayes-Genis, Paloma Gastelurrutia, Maria-Luisa Cámara, Albert Teis, Josep Lupón, Cinta Llibre, Elisabet Zamora, Xavier Alomar, Xavier Ruyra, Santiago Roura, Ana Revilla, José Alberto San Román, Carolina Gálvez-Montón

Abstract

Background: The present study evaluates the safety and efficacy of the Adipose Graft Transposition Procedure (AGTP) as a biological regenerative innovation for patients with a chronic myocardial scar.

Methods: This prospective, randomized single-center controlled study included 10 patients with established chronic transmural myocardial scars. Candidates for myocardial revascularization were randomly allocated into two treatment groups. In the control arm (n=5), the revascularizable area was treated with CABG and the non-revascularizable area was left untouched. Patients in the AGTP-treated arm (n=5) were treated with CABG and the non-revascularizable area was covered by a biological adipose graft. The primary endpoint was the appearance of adverse effects derived from the procedure including hospital admissions and death, and 24-hour Holter monitoring arrhythmias at baseline, 1week, and 3 and 12months. Secondary endpoints of efficacy were assessed by cardiac MRI.

Findings: No differences in safety were observed between groups in terms of clinical or arrhythmic events. On follow-up MRI testing, participants in the AGTP-treated arm showed a borderline smaller left ventricular end systolic volume (LVESV; p=0.09) and necrosis ratio (p=0.06) at 3months but not at 12months. The AGTP-treated patient with the largest necrotic area and most dilated chambers experienced a noted improvement in necrotic mass size (-10.8%), and ventricular volumes (LVEDV: -55.2mL and LVESV: -37.8mL at one year follow-up) after inferior AGTP.

Interpretation: Our results indicate that AGTP is safe and may be efficacious in selected patients. Further studies are needed to assess its clinical value. (ClinicalTrials.org NCT01473433, AdiFlap Trial).

Keywords: Adipose tissue; Cardiac surgery; Cardiac tissue engineering; Myocardial infarction; Regenerative medicine; Stem cell therapy.

Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Figures

Fig. 1
Fig. 1
Study design. n: number of patients, CABG: coronary artery bypass graft, AGTP: Adipose Graft Transposition Procedure, MRI: magnetic resonance imaging.
Fig. 2
Fig. 2
Schematic illustration of the Adipose Graft Transposition Procedure (AGTP). Pericardial adipose tissue is dissected to create the graft (A). After partial pericardiectomy, MI is located (B) and the pericardial adipose graft is transposed onto the infarct area and glued on healthy edges (C), covering the ischemic myocardium (D). The figure was designed and hand-drawn by CG-M.
Fig. 3
Fig. 3
MRI analysis: Representative T1 short-axis delayed enhancement images rev`eal healthy (black) and infarcted myocardium (white) for AGTP-treated and control patients at baseline and 12 months. Arrowheads point out the attached adipose graft position in the treated patients. Histograms represent changes in percentage of necrotic tissue from baseline to three months in treated and control patients.
Fig. 4
Fig. 4
Selected patient case: short-axis delayed enhanced images show the healthy (black) and infarcted myocardium (white) before and after AGTP; 4-chamber view shows patient's volumes before and after AGTP. Arrows point out the attached adipose graft position in the treated patient. ECG shows a Q wave in leads III and aVF at baseline that is not present at follow-up ECGs.

References

    1. Ahima R.S., Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 2000;11:327–332.
    1. Amado L.C., Gerber B.L., Gupta S.N. Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model. J. Am. Coll. Cardiol. 2004;44:2383–2389.
    1. Anon. Global Status Report on Noncommunicable Diseases 2010. World Health Organization; 2011 April. Burden: mortality, morbidity and risk factors; p. 9. (Chapter 1, ISBN: 978 92 4 156422 9)
    1. Bagó J.R., Soler-Botija C., Casaní L. Bioluminescence imaging of cardiomyogenic and vascular differentiation of cardiac and subcutaneous adipose tissue-derived progenitor cells in fibrin patches in a myocardium infarct model. Int. J. Cardiol. 2013;169:288–295.
    1. Bayes-Genis A1., Soler-Botija C., Farré J. Human progenitor cells derived from cardiac adipose tissue ameliorate myocardial infarction in rodents. J. Mol. Cell. Cardiol. 2010;49:771–780.
    1. Bayes-Genis A., Gálvez-Montón C., Prat-Vidal C., Soler-Botija C. Cardiac adipose tissue: a new frontier for cardiac regeneration? Int. J. Cardiol. 2013;167:22–25.
    1. Flett A.S., Hasleton J., Cook C. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. J. Am. Coll. Cardiol. Img. 2011;4:150–156.
    1. Gálvez-Montón C., Prat-Vidal C., Roura S. Transposition of a pericardialderived vascular adipose flap for myocardial salvage after infarct. Cardiovasc. Res. 2011;91:659–667.
    1. Gálvez-Montón C., Prat-Vidal C., Roura S., Soler-Botija C., Bayes-Genis A. Update: Innovation in cardiology (IV). Cardiac tissue engineering and the bioartificial heart. Rev. Esp. Cardiol. 2013;66:391–399.
    1. Gálvez-Montón C., Prat-Vidal C., Roura S. Post-infarction scar coverage using a pericardial-derived vascular adipose flap. Pre-clinical results. Int. J. Cardiol. 2013;166:469–474. (20)
    1. Kellman P., Bandettini W.P., Mancini C., Hammer-Hansen S., Hansen M.S., Arai A.E. Characterization of myocardial T1-mapping bias caused by intramyocardial fat in inversion recovery and saturation recovery techniques. J. Cardiovasc. Magn. Reson. 2015;17:33.
    1. Kramer C., Barkhausen J., Flamm S.D., Kim R., Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for Cardiovascular Magnetic Resonance: Board of Trustees Task Force on Standardized Protocols. J. Cardiovasc. Magn. Reson. 2008;10:35.
    1. Messroghli D.R., Radjenovic A., Kozerke S., Higgins D.M., Sivananthan M.U., Ridgway J.P. Modified Look–Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn. Reson. Med. 2004;52:141–146.
    1. Messroghli D.R., Walters K., Plein S. Myocardial T1 mapping: application to patients with acute and chronic myocardial infarction. Magn. Reson. Med. 2007;58:34–40.
    1. Moon J.C., Messroghli D.R., Kellman P. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J. Cardiovasc. Magn. Reson. 2013;15:92.
    1. Motegi S., Tamura A., Abe M., Okada E., Nagai Y., Ishikawa O. Reverse latissimus dorsi musculocutaneous flap for reconstruction of lumbar radiation ulcer. J. Dermatol. 2007;34:565–569.
    1. Prat-Vidal C., Gálvez-Montón C., Puig-Sanvicens V. Online monitoring of myocardial bioprosthesis for cardiac repair. Int. J. Cardiol. 2014;174:654–661.
    1. Rocha L.S., Paiva G.R., de Oliveira L.C., Filho J.V., Santos I.D., Andrews J.M. Frontal reconstruction with frontal musculocutaneous V-Y island flap. Plast. Reconstr. Surg. 2007;120:631–637.
    1. Roura S., Soler-Botija C., Bagó J.R. Postinfarction functional recovery driven by a three-dimensional engineered fibrin patch composed of human umbilical cord blood-derived mesenchymal stem cells. Stem Cells Transl. Med. 2015;4:956–966.
    1. San Roman J.A., Sánchez P.L., Villa A. Comparison of different bone marrow-derived stem cell approaches in reperfused STEMI. A multicenter, prospective, randomized, open-labeled TECAM trial. J. Am. Coll. Cardiol. 2015;65:2372–2382.
    1. Simonetti O.P., Kim R.J., Fieno D.S. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218:215–223.
    1. Soler-Botija C., Bagó J.R., Bayes-Genis A. A bird's-eye view of cell therapy and tissue engineering for cardiac regeneration. Ann. N. Y. Acad. Sci. 2012;1254:57–65.
    1. Stone G.W., Teirstein P.S., Rubenstein R. A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions. J. Am. Coll. Cardiol. 2002;39:1581–1587.
    1. Sweeney G. Cardiovascular effects of leptin. Nat. Rev. Cardiol. 2010;7:22–29.
    1. Unger E.F., Sheffield C.D., Epstein S.E. Creation of anastomoses between an extracardiac artery and the coronary circulation. Proof that myocardial angiogenesis occurs and can provide nutritional blood flow to the myocardium. Circulation. 1990;82:1449–1466.
    1. White S.K., Sado D.M., Fontana M. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. J. Am. Coll. Cardiol. Img. 2013;6:955–962.

Source: PubMed

3
Předplatit